Rescriptor and Hyphaema - a phase IV clinical study of FDA data
Summary:
We study 1,110 people who take Rescriptor (delavirdine mesylate) or have Hyphaema. No report of Hyphaema is found in people who take Rescriptor.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Rescriptor?
Rescriptor has active ingredients of delavirdine mesylate. eHealthMe is studying from 426 Rescriptor users. Check the latest studies of Rescriptor.
What is Hyphaema?
Hyphaema (collection of blood inside the front part of the eye) is found to be associated with 89 drugs and 123 conditions by eHealthMe. Check the latest studies of Hyphaema.
No report is found.
Do you take Rescriptor and have Hyphaema?
- Check whether Hyphaema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Rescriptor:
- Rescriptor (426 reports)
Hyphaema treatments and more:
- Hyphaema (684 reports)
How severe was Hyphaema and when was it recovered:
Expand to all the drugs that have ingredients of delavirdine mesylate:
Browse all side effects of Rescriptor:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Hyphaema:
Browse all the conditions that are associated with Hyphaema:
How the study uses the data?
The study uses data from the FDA. It is based on delavirdine mesylate (the active ingredients of Rescriptor) and Rescriptor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Naprosyn and Xeljanz - 8 seconds ago
- Sciatica and drugs of ingredients of primidone - 10 seconds ago
- Tenormin and Hyzaar drug interactions for men aged 60+ - 14 seconds ago
- Could Diazepam cause Histiocytosis Haematophagic? - 15 seconds ago
- Glucophage and Angiopathy for Women aged 60+ - 15 seconds ago
- Drug interactions of Veletri and Spiriva - 16 seconds ago
- Could Doxazosin Mesylate cause Intervertebral Disc Space Narrowing? - 22 seconds ago
- Tysabri and Solu-Medrol drug interactions for women aged 20-29 - 26 seconds ago
- Drug interactions of Aloxi and Ms Contin - 34 seconds ago
- Fentanyl Citrate and Constipation Aggravated for Men aged 60+ - 37 seconds ago